Case Report

Case treated with triple therapy of lamivudine, interferon-β and prednisolone for acute exacerbation of chronic hepatitis B during pregnancy

Maki Koh,1 Jun Shinohara,1 Yasushi Hongo,2 Tadashi Okazaki,3 Kimitaka Takitani4 and Hiroshi Tamai4

Departments of 1Pediatrics, 2Gastroenterology and Hepatology, and 3Obstetrics and Gynecology, Hirakata City Hospital, Hirakata, and 4Department of Pediatrics, Osaka Medical College, Takatsuki, Japan

We herein report a case of a pregnant Chinese woman who suffered an acute exacerbation of hepatitis B. The patient's liver enzymes became elevated toward the end of the first trimester. She was treated with lamivudine, interferon (IFN)-β and steroids early in the second trimester. After this treatment regimen was initiated, aminotransferase levels rapidly normalized within 4 weeks. IFN-β and steroids were administered for 2 weeks in the second trimester, while the administration of lamivudine continued until delivery. The spontaneous delivery of a female baby weighing 2984 g occurred at 37 weeks of gestation. A neonatal examination revealed no congenital anomalies, and fetal growth was found to be within normal reference ranges. The infant received simultaneous active and passive hepatitis B virus immunization within 12 h of delivery and completed the hepatitis B vaccine schedule at 2, 3 and 5 months of age. The infant was successfully prevented from contracting hepatitis B virus. This case suggests that combination therapy with lamivudine, IFN-β and steroids may be safely used during the second trimester to treat acute exacerbations of hepatitis B.

Key words: hepatitis B virus, interferon-β, lamivudine, maternal-infant transmission, pregnancy, steroid

INTRODUCTION

HEPATITIS B INFECTION is a major medical problem worldwide and causes acute hepatic failure, chronic hepatitis and hepatocellular carcinoma.1,2 Approximately one-third of the world’s population has a history of hepatitis B virus (HBV) infection. In addition, approximately 350–400 million people are chronically infected with HBV.3 HBV infection occurs through vertical or horizontal transmission during infancy and childhood.3–5 Passive-active immunoprophylaxis with hepatitis B immunoglobulins and the hepatitis B vaccine given at birth is 95% effective at reducing HBV transmission;6,7 however, vertical transmission of hepatitis B can occur in children despite vaccination. Vaccination breakthrough is associated with high levels of maternal viremia.8–11 Maternal HBV infection has been reported to be associated with a high incidence of low birthweight and premature birth.12 Moreover, acute exacerbations of HBV during pregnancy are associated with high rates of maternal and perinatal mortality.12,13 Currently, no consensus exists regarding the safety of particular treatments for the acute exacerbations of HBV that occur during pregnancy;14 however, some data exist to support the use of lamivudine to reduce viral loads.15–18 Therefore, the selection of therapy to treat HBV during pregnancy requires careful consideration. In this report, we describe a case of acute exacerbation of HBV during pregnancy that was treated with lamivudine, interferon (IFN)-β and steroids. This therapy regimen successfully improved maternal liver function and reduced the maternal HB viral load. Furthermore, passive and active immunoprophylaxis prevented the perinatal transmission of HBV to the infant.

CASE REPORT

THIS CASE INVOLVED the second child conceived between a Chinese mother and a Japanese father. The mother was a hepatitis B carrier and her first child...
had been vaccinated against HBV. The mother was admitted to Hirakata City Hospital at 25 years of age and 15 weeks of gestation. She was found to be negative for hepatitis B e antibody and positive for hepatitis B surface antigen and hepatitis B e-antigen. On admission, her serum aspartate aminotransferase (AST) level measured 915 IU/L, her alanine aminotransferase (ALT) level measured 706 IU/L and her serum HBV DNA showed a high level of 8.2 log copies/mL. The laboratory data indicated an acute exacerbation of hepatitis B. At 18⁴⁄₆ weeks of gestation, the patient’s ALT level measured 910 IU/L, AST 1426 IU/L and total bilirubin 3.55 mg/dL (Table 1). As the patient was developing liver damage, treatment with lamivudine (100 mg/day) was started (Fig. 1). The Ethical Practices Committee of Hirakata City Hospital approved the study protocol during pregnancy, and the patient gave informed consent. At 19⁺² weeks of gestation, the patient’s aminotransferase levels and hepatic function tests were found to be impaired: ALT, 1250 IU/L; AST, 1892 IU/L; total bilirubin, 5.25 mg/dL; and prothrombin time, 57.2%. In spite of lamivudine administration, aggravation of serum transaminase, total bilirubin and prothrombin time occurred. Thus, the patient was given IFN-β therapy (3 MIU) and methylprednisolone therapy.

### Table 1 Laboratory findings of the mother with acute exacerbation of hepatitis B virus

| Laboratory test                        | Levels        | Reference range |
|----------------------------------------|---------------|-----------------|
| White blood cells (10³/µL)             | 7.6           | (4.7–8.7)       |
| Red blood cells (10³/µL)               | 3.91          | (3.70–4.90)     |
| Hemoglobin (g/dL)                      | 12.4          | (12.0–16.0)     |
| Platelets (10³/µL)                     | 195           | (150–400)       |
| Aspartate aminotransferase (IU/L)      | 1,426         | (8–38)          |
| Alanine aminotransferase (IU/L)        | 910           | (4–44)          |
| Lactate dehydrogenase (IU/L)           | 475           | (106–211)       |
| γ-Glutamyl transpeptidase (IU/L)       | 51            | (16–73)         |
| Cholinesterase (IU/L)                  | 120           | (185–431)       |
| Total protein (g/dL)                   | 5.6           | (6.7–8.3)       |
| Albumin (g/dL)                         | 2.8           | (3.8–5.3)       |
| Ammonia (µg/dL)                        | 24            | (12–66)         |
| Total bilirubin (mg/dL)                | 3.55          | (0.2–1.2)       |
| Direct bilirubin (mg/dL)               | 2.46          | (0.00–0.4)      |
| Total cholesterol (mg/dL)              | 158           | (130–219)       |
| Blood urea nitrogen (mg/dL)            | 5.3           | (7–18)          |
| Creatinine (mg/dL)                     | 0.42          | (0.4–0.8)       |
| Na (mEq/L)                             | 138           | (135–145)       |
| K (mEq/L)                              | 3.8           | (3.5–5.0)       |
| Prothrombin time (%)                   | 97.9          | (60–100)        |
| Prothrombin time – International
  Normalized Ratio                        | 1.02          | (0.95–1.35)     |

Figure 1 Clinical course of HBV mother with acute exacerbation. ALT, alanine aminotransferase; HBV, hepatitis B virus; IFN-β, interferon-β; mPSL, methylprednisolone; PT, prothrombin time; T-Bil, total bilirubin.
The patient’s aminotransferase levels rapidly normalized within 4 weeks: ALT, 24 IU/L; AST, 28 IU/L; and HBV DNA, 3.8 log copies/mL. IFN-β and steroids (total dose: methylprednisolone 4200 mg and prednisolone 90 mg) were administered for 2 weeks during the second trimester, and the administration of lamivudine (100 mg/day) was continued until delivery. At 36 weeks of gestation, the patient’s serum HBV DNA level had decreased to 2.2 log copies/mL. The spontaneous delivery of a female baby weighing 2984 g occurred at 37+6 weeks of gestation. The neonate showed Apgar scores of 9 and 10 at 1 and 5 min, respectively. Fetal growth was found to be within normal reference ranges and a neonatal physical examination revealed no congenital anomalies. Passive immunization with HB immunoglobulins was injected immediately after delivery. The infant completed the HB vaccine schedule at 2, 3 and 5 months of age (Fig. 2). The infant was successfully prevented from contracting HBV infection. The infant received follow-up visits until 1.5 years of age and no adverse effects on the infant’s health or development were observed.

**DISCUSSION**

In this case, sequential therapy with lamivudine, IFN-β and steroids was administrated during the second trimester to treat an acute exacerbation of HB. This therapy reduced the maternal HBV DNA viral load without showing any negative effects on the fetus. Intensive treatment of HBV after second trimester exposure has been proven to be well-tolerated. Moreover, comprehensive immunoprophylaxis for infants can prevent the transmission of HBV. However, the balance of the potential benefits and risks of treatment of HB infection during pregnancy for both the mother and the infant should be considered. Currently, data exist to support maternal treatment with lamivudine in order to reduce HBV DNA levels. Lamivudine, an oral cytosine nucleoside analog, has been widely used in pregnant women with HIV because it is efficacious and well-tolerated. Furthermore, lamivudine therapy has been proven to be effective in HBV-infected pregnant women and its use in pregnancy is likely to be advisable. In the present case, lamivudine therapy alone did not improve maternal liver function. An acute exacerbation of HB during pregnancy is a critical complication that is associated with maternal and prenatal mortality. After administering lamivudine therapy, we decided to initiate treatment with IFN-β and steroids (methylprednisolone followed by prednisolone) in order to prevent the development of hepatitis.

IFN-β may not be considered safe for use during pregnancy due to its anti-proliferative effects. The US Food and Drug Administration classifies IFN as a pregnancy category C drug (animal reproduction studies have shown adverse effects of IFN on fetuses, and there exist no well-controlled studies in humans). IFN-β is an immunomodulator that is used to prevent relapse and progression in patients with multiple sclerosis (MS). Several clinical studies have proven that in utero exposure to IFN-β during pregnancy occurs in patients with MS; however, results regarding the effects of IFN-β on pregnant mothers and newborns have been conflicting. Boskovic and colleagues reported that exposure to IFN-β in the first trimester increases the risk for miscarriages, stillbirth and low infant birthweight. A study by Amato et al. revealed that IFN-β exposure does not increase the risk of spontaneous abortion and is not associated with any significant fetal complications, malformations or developmental abnormalities; however, this study found that IFN-β exposure is associated with low birthweight and shorter length in newborns. Other recent studies on in utero exposure to IFN-β in patients with MS have shown that IFN-β does not affect maternal or infant outcomes. However, no previous studies have so far investigated the in utero exposure in patients with HBV infection. In the present case, the patient was treated with IFN-β for 2 weeks in the second trimester. This report suggests that the use of IFN to treat HBV infection is beneficial, not only for improving liver function, but also for reducing HBV viral loads.

The administration of steroid therapy during pregnancy may potentially influence the incidence of
intrauterine growth retardation. For steroids, the risk to the fetus is correlated with the transplacental passage rate. Because prednisolone is inactivated by 11β-hydroxysteroid dehydrogenase in the placenta, the effects of steroid use on the fetus during pregnancy may be small. On the other hand, methylprednisolone passes through the placental barrier, and fetal levels of methylprednisolone are typically approximately one-third of maternal levels. Therefore, we were aware that the potential benefits of these agents outweighed the potential risks for both the mother and the fetus, and these agents were administrated with discretion. In this case, combination therapy with lamivudine, IFN-β and steroids administrated during the second trimester has achieved sufficient reductions in maternal HBV DNA levels.

Regarding the prevention of perinatal HBV transmission, some studies have reported beneficial effects from the use of HBV vaccines and hepatitis B immunoglobulins in infants. Passive–active immunoprophylaxis in infants in combination with maternal therapy to reduce HBV DNA levels can prevent maternal–infant HBV transmission. This case report demonstrates the potential efficacy and safety of treatment with lamivudine, IFN-β and steroids during the second trimester. However, there is the limitation of this being a case report, so further clinical studies are needed to evaluate the efficacy and safety of maternal therapy with these agents to treat acute exacerbations of HBV during pregnancy.

ACKNOWLEDGMENTS

We wish to express our appreciation to Dr T. Tanaka and Dr H. Fujii for their expert advice.

REFERENCES

1 Alter MJ. Epidemiology if hepatitis B in Europe and worldwide. J Hepatol 2003; 39: S64–9.
2 World Health Organization. Hepatitis B: World Health Organization fact sheet 204. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed August 23, 2012.
3 Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996; 38: S39–42.
4 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–2.
5 Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771–4.
6 Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Br Med J 2006; 332: 328–36.
7 Ip HM, Lelie PN, Wong VC, Kuhrns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1: 406–10.
8 Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170: 1418–23.
9 Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489–92.
10 Xu DZ, Yan YP, Choi BC et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67: 20–6.
11 Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998; 27: 100–6.
12 Li XM, Ma L, Yang YB, Shi ZL, Zhou SS. Clinical characteristics of fulminant hepatitis in pregnancy. World J Gastroenterol 2005; 11: 4600–3.
13 Sookoian S. Liver disease during pregnancy: acute viral hepatitis. Ann Hepatol 2006; 5: 231–6.
14 Degli Esposti S, Shah D. Hepatitis B in pregnancy: challenges and treatment. Gastroenterol Clin North Am 2011; 40: 355–72.
15 Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94–103.
16 van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294–7.
17 Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10: 910–12.
18 Hung JH, Chu CJ, Sung PL et al. Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. J Chin Med Assoc 2008; 71: 155–8.
19 Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173–80.
20 Culhane M, Fowler M, Lee SS et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281: 151–7.
21 Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827–43.

22 Bzowej NH. Hepatitis B therapy in pregnancy. Curr Hepat Rep 2010; 9: 197–204.

23 Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2009. Wilmington, NC: Registry Coordinating Center, 2008; Available at: http://www.apregistry.com/forms/interim_report.pdf. Accessed August 23, 2012.

24 Peters MG. Special populations with hepatitis B virus infection. Hapatology 2009; 49: S146–55.

25 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hapatology 2007; 45: 1056–75.

26 US Food and Drug Administration. Toxicologist’s review, PLA#98-0261, recombinant human interferon-β1a. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm106138.pdf. Accessed August 23, 2012.

27 Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007; 7: 227–39.

28 Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807–11.

29 Amato MP, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010; 75: 1794–802.

30 Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802–6.

31 Patti F, Cavallaro T, Lo Fermo S et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 2008; 255: 1250–3.

32 Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115: 3–9.

33 Miller NM, Williamson C, Fisk NM, Glover V. Infant cortisol response after prolonged antenatal prednisolone treatment. BJOG 2004; 111: 1471–4.

34 Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81: 936–45.

35 Anderson GG, Rotchell Y, Kaiser DG. Placental transfer of methylprednisolone following maternal intravenous administration. Am J Obstet Gynecol 1981; 140: 699–701.